Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

May

Today In Oncology

Providing Culturally Sensitive Palliative Care to Children With Cancer

Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival

Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer Comparison of Agents

FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC

Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos